침윤성 방광이행세포암에 대한 신보조적 M-VAC(Methotrexate, Vinblastine, Adriamycin and Cisplatin)의 화학요법의 효과
Neoadjuvant M-VAC(Methotrexate, Vinblastine, Adriamycin and Cisplatin) Effect on the Invasive Bladder Tumor
오주현, 윤정한,
소속 상세정보
오주현 ( )
전북대학교 의과대학 미생물학교실
윤정한 ( )
전남대학교
KMID : 0358319960370030293
Abstract
We evaluated the effect of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in 63 patients with invasive transitional cell carcinoma of the bladder between January 1987and December 1993. The patients consisted of 59 male
and
4
female. Patient age ranged from 35 to 80 years with a mean of 61.5 years. All patients were given 1-7 cycles(mean 2.7 cycles) of M-VAC chemotherapy and followed for 1 to 8 years.
Ten patients916%) achieved a clinical complete remission(CR), 22(35%) partial remission(PR), 11(17.5%) minor response(MR), 11(17.5%) stabilization(STAB), and 9(14%) progression(PROG). The overall clinical response rate was 51%. Of 22patients who
underwent surgery(radical cystectomy in 15, partectomy in 7), 3 patients(14%) achieved objective pathologic response. The estimated 5-year survival rate according to response of primary tumor to chemotherapy was 86%, 55% in patients with response
and
non-respectively. This difference between the groups was statistically significant(P<0.05). Overall 3-years and 5-yearss survival rates were 73% and 71%, respectively, and mean survival was 3.1 yeas. The toxicity of the regimen was generally
acceptable,
but 79% of the patients experienced myelosuppression, 8% hepatic toxicity and 6% stomatitis.
In conclusion, the patients who achieved a clinical response seem to have a better prognosis and neoadjuvant M-VAC chemotherapy may result in bladder preservation for selected patients with muscle invasive bladder cnacer.
키워드
원문 및 링크아웃 정보
등재저널 정보